KDM1B inhibition can prevent the expansion of cancer stem cells induced by IFN-I [40]; KDM6B deletion can enhance a series of immune pro-inflammatory pathways such as interferon response, antigen presentation and phagocytosis in the glioblastoma (GBM) tumor immune microenvironment, indicating that KDM6B inhibition can overcome myeloid-derived immune suppression and enhance response to immunotherapy in GBM [41]. This evidence concerns the gene KDM6B and glioblastoma.